Description: Obstructive sleep apnea (OSA) is associated with cardiometabolic diseases. Telomere shortening is linked to hypertension, diabetes mellitus, and cardiovascular diseases. Because these conditions are highly prevalent in OSA, we hypothesized that telomere length (TL) would be reduced in OSA patients. We identified 106 OSA and 104 non-OSA subjects who underwent polysomnography evaluation. Quantitative PCR was used to measure telomere length in genomic DNA isolated from peripheral blood samples. The association between OSA and TL was determined using unadjusted and adjusted linear models. There was no difference in TL between the OSA and non-OSA (control) group. However, we observed a J-shaped relationship between TL and OSA severity: the longest TL in moderate-to-severe OSA [4,918 ± 230 (SD) bp] and the shortest TL in mild OSA (4,735 ± 145 bp). Mean TL in moderate-to-severe OSA was significantly longer than in the control group after adjustment for age, sex, body mass index, hypertension, dyslipidemia, and depression (β = 96.0, 95% confidence interval: 15.4–176.6, P = 0.020). In conclusion, moderate-to-severe OSA is associated with telomere lengthening. Our findings support the idea that changes in TL are not unidirectional processes, such that telomere shortening occurs with age and disease but may be prolonged in moderate-to-severe OSA. NEW & NOTEWORTHY Here, we show that moderate-to-severe obstructive sleep apnea is associated with longer telomeres, independent of age and cardiovascular risk factors, challenging the hypothesis that telomere shortening is a unidirectional process related to age/disease. A better understanding of the mechanisms underlying telomere dynamics may identify targets for therapeutic intervention in cardiovascular aging/other chronic diseases.

Description: Empirical algorithms are developed using high-quality GO-SHIP hydrographic measurements of commonly measured parameters (temperature, salinity, pressure, nitrate, and oxygen) that estimate pH in the Pacific sector of the Southern Ocean. The coefficients of determination, R 2 are 0.98 for pH from nitrate (pH N ) and 0.97 for pH from oxygen (pH Ox ) with RMS errors of 0.010 and 0.008, respectively. These algorithms are applied to Southern Ocean Carbon and Climate Observations and Modeling (SOCCOM) biogeochemical profiling floats, which include novel sensors (pH, nitrate, oxygen, fluorescence, and backscatter). These algorithms are used to estimate pH on floats with no pH sensors, and to validate and adjust pH sensor data from floats with pH sensors. The adjusted float data provide, for the first time, seasonal cycles in surface pH on weekly resolution that range from 0.05 to 0.08 on weekly resolution for the Pacific sector of the Southern Ocean.

Description: Synthetic cathinones are components of "bath salts" and have physical and psychologic side effects, including hypertension, paranoia, and hallucinations. Here, we report interactions of 20 "bath salt" components with human dopamine, serotonin, and norepinephrine transporters [human dopamine transporter (hDAT), human serotonin transporter (hSERT), and human norepinephrine transporter (hNET), respectively] heterologously expressed in human embryonic kidney 293 cells. Transporter inhibitors had nanomolar to micromolar affinities (K i values) at radioligand binding sites, with relative affinities of hDAT〉hNET〉hSERT for α -pyrrolidinopropiophenone ( α -PPP), α -pyrrolidinobutiophenone, α -pyrrolidinohexiophenone, 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone, 3,4-methylenedioxy- α -pyrrolidinopropiophenone, 3,4-methylenedioxy- α -pyrrolidinobutiophenone, 4-methyl- α -pyrrolidinopropiophenone, α -pyrrolidinovalerophenone, 4-methoxy- α -pyrrolidinovalerophenone, α -pyrrolidinopentiothiophenone (alpha-PVT), and α -methylaminovalerophenone, and hDAT〉hSERT〉hNET for methylenedioxypentedrone. Increasing the α -carbon chain length increased the affinity and potency of the α -pyrrolidinophenones. Uptake inhibitors had relative potencies of hDAT〉hNET〉hSERT except α -PPP and α -PVT, which had highest potencies at hNET. They did not induce [ 3 H]neurotransmitter release. Substrates can enter presynaptic neurons via transporters, and the substrates methamphetamine and 3,4-methylenedioxymethylamphetamine are neurotoxic. We determined that 3-fluoro-, 4-bromo-, 4-chloro-methcathinone, and 4-fluoroamphetamine were substrates at all three transporters; 5,6-methylenedioxy-2-aminoindane (MDAI) and 4-methylethcathinone (4-MEC) were substrates primarily at hSERT and hNET; and 3,4-methylenedioxy- N -ethylcathinone (ethylone) and 5-methoxy-methylone were substrates only at hSERT and induced [ 3 H]neurotransmitter release. Significant correlations between potencies for inhibition of uptake and for inducing release were observed for these and additional substrates. The excellent correlation of efficacy at stimulating release versus K i /IC 50 ratios suggested thresholds of binding/uptake ratios above which compounds were likely to be substrates. Based on their potencies at hDAT, most of these compounds have potential for abuse and addiction. 4-Bromomethcathinone, 4-MEC, 5-methoxy-methylone, ethylone, and MDAI, which have higher potencies at hSERT than hDAT, may have empathogen psychoactivity.